EBV Related PTCL clinical trials at UCSF
1 research study open to eligible people
EBV related PTCL is a lymphoma, a cancer of lymph nodes, caused by Epstein-Barr virus. UCSF is carrying out trials to see how well nanatinostat and valganciclovir work together to fight this cancer. These are phase 2 trials, where we check if the treatment works.
Showing trials for
Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
open to eligible people ages 18 years and up
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas
San Francisco, California and other locations
Last updated: